The Genomic Medicine Alliance is a global research network aiming to create collaboration ties between academics, researchers, regulators, and the general public interested in all aspects of genomics and personalized medicine.
The Alliance provides the means to establish networks and to encourage collaborative work towards advancing the Genomic Medicine discipline, focusing in particular on translating results from academic research into clinical practice.
In particular, the Genomic Medicine Alliance aims to:
- Encourage and catalyze multidisciplinary collaborative research between partner institutions and scientists, particularly from emerging countries.
- Liaise among research organizations, clinical entities and regulatory agencies in areas related to genomic medicine.
- Facilitate the introduction of pharmacogenomics and advanced omics technologies into the mainstream clinical practice.
- Produce and propose guidelines and recommendations in all areas pertaining to genomic medicine, always in close collaboration with other scientific academic entities, agencies and regulatory bodies.
- Develop, independently or in close collaboration with partner institutions, and coordinate educational activities in the area of genomic medicine.
The Genomic Medicine Alliance activities are divided into 8 Working Groups, namely Genome Informatics, Pharmacogenomics, Cancer Genomics, Rare Diseases, Public Health Genomics, Economic evaluation in Genomic Medicine, Genethics, and Quality Assurance.
The Genomic Medicine Alliance research activities are coordinated by a multinational 18-member Scientific Advisory Committee, while administrative support is provided by the Golden Helix Foundation.
Since 2014, Public Health Genomics has become the Official journal of the Genomic Medicine Alliance.
